在外部质量评估计划中对第八因子延长半衰期产品测量的表现.
Anna Williams1, Piet Meijer2, Elysse Dean3
1UK NEQAS BC, Sheffield, UK.
International journal of laboratory hematology
|January 14, 2026
概括
目前用于监测血友病A患者的第八因子 (FVIII) 水平的实验室测定显示与新延长半衰期 (EHL) 产品不一致. 这些测量变化可能导致不准确的患者治疗和潜在的临床风险.
科学领域:
- 临床诊断 临床诊断 临床诊断
- 血友病是一种管理方式.
- 药理动力学是什么 药理动力学
背景情况:
- 改善了对血友病A的治疗方法,提高了患者的生活质量.
- 监测患者的第八因子 (FVIII) 水平对于预防治疗不足或过度治疗至关重要.
- 新的延长半衰期 (EHL) 产品对实验室监测提出了挑战.
研究的目的:
- 在全球实验室队列中调查FVIII测定结果的差异.
- 在常规实验室监测中识别新型FVIII EHL产品所带来的挑战.
- 用 EHL FVIII 产品评估常见实验室检测的性能.
主要方法:
- 2023年的一项全球研究涉及将样分发给众多实验室.
- 测试了五种不同的FVIII EHL产品.
- 外部质量评估 (EQA) 计划 (ECAT,NEQAS,RCPAQAP) 促进了样本的分配.
主要成果:
- 实验室使用了一阶段测定 (OSA) 或染色体测定 (CA).
- 特定的试剂通常用于OSA (例如IL Hemosil Synthasil,西门子Actin FS) 和CA (例如Chromogenix Coamatic FVIII,西门子染色FVIII).
- 结果表明,目前的OSA和CA并不一致地量化某些EHL产品的FVIII水平.
结论:
- 现有的OSA和CA在检测EHL产品的FVIII水平方面表现异常,导致潜在的低估或高估.
- 不一致的结果表明,新型FVIII疗法目前的测定方法存在局限性.
- 需要进一步澄清对测定结果的解释,特别是对于像Afstyla Lonoctocog alfa这样的产品,关于校正因子.
相关概念视频
01:14Drug Dissolution: Requirements and Profile Comparison
236
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
236
01:20Drug Product Performance: In Vitro–In Vivo Correlation
228
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
228
01:20Measurement of Bioavailability: Pharmacodynamic Methods
230
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
230